Drug Trial Radar · NCT05966701
The MAD Study of SSGJ-613 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 10, 2023
Primary completion
Mar 10, 2024
Study completion Mar 10, 2024
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.
Conditions
- Arthritis, Gouty
Interventions
SSGJ-613Drug
SSGJ-613 subcutaneous injection.
PlaceboDrug
Placebo subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs), measurement of vital signs,physical examination,electrocardiogram and laboratory tests at each visit.Time frame: Up to Day 174
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui District Central Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.